Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Provenge (sipuleucel-T; Sanpower Group) Drug Analysis: A Cellular Immunotherapy Composed of Autologous Dendritic Cells Loaded with the Recombinant Antigen Prostatic Acid Phosphatase - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Provenge" drug pipelines has been added to ResearchAndMarkets.com's offering.

Drug Overview

Provenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed on approximately 95% of prostate tumor cells. The vaccine is administered alongside a granulocyte-macrophage colony-stimulating factor adjuvant. Upon injection, the PAP-loaded dendritic cells cause activation of T cells, which recognize the target antigen and destroy prostate tumor cells.

Key Topics Covered:

List of Figures

Figure 1: Provenge for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Provenge for prostate cancer

Figure 3: Drug assessment summary of Provenge for prostate cancer

Figure 4: Provenge sales for prostate cancer in the US, 2017-26

List of Tables

Table 1: Provenge drug profile

Table 2: Provenge pivotal Phase III data in prostate cancer

Table 3: Provenge sales for prostate cancer in the US ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/dbmt8f/2018_provenge?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005584/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.